← 返回

新型免疫检查点 GPR56 在 TIL(肿瘤浸润淋巴细胞)上表达并在 TCR 信号传导后选择性上调

英文原题:The Novel Immune Checkpoint GPR56 Is Expressed on Tumor-Infiltrating Lymphocytes and Selectively Upregulated upon TCR Signaling.

查看英文原题

The Novel Immune Checkpoint GPR56 Is Expressed on Tumor-Infiltrating Lymphocytes and Selectively Upregulated upon TCR Signaling.

PubMed 2022/06/28(内容时间) Cancers (Basel) Q2 · IF 4.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肿瘤微环境(TME)中较高水平的TIL(肿瘤浸润淋巴细胞)与多种癌症的生存获益相关;靶向(再)激活TIL是一种有吸引力的抗癌治疗方法,可带来治愈性应答。

然而,针对已知免疫检查点的现有T细胞靶向策略并未提高所有癌症(包括上皮性卵巢癌EOC)的客观缓解率。因此,识别调节T细胞免疫的新型检查点仍备受关注。一个尚未充分研究、但可能具有意义的检查点是G蛋白偶联受体56(GPR56),它属于黏附型GPCR家族。既往研究发现GPR56参与大脑皮层发育和抗抑郁反应,也与癌症有关。近期研究显示,GPR56是人NK细胞上的抑制性受体,可通过与四跨膜蛋白CD81顺式相互作用而减弱NK细胞细胞毒性;抗GPR56抗体阻断这一NK细胞检查点可增强细胞毒性。有趣的是,细胞因子产生型记忆CD8 T淋巴细胞也表达GPR56,因此它可能同样是T细胞检查点。

本研究在TIL背景下分析了GPR56 mRNA表达,发现GPR56主要见于具有细胞毒性和(预)耗竭表型的肿瘤浸润CD8 T细胞。与这一mRNA特征一致,卵巢癌患者TIL中的GPR56主要表达于效应记忆和中央记忆T细胞亚群;健康供者T细胞中的表达则限于效应记忆及终末分化T细胞。

值得注意的是,在与癌细胞共培养时,T细胞受体(TCR)介导的刺激进一步提高TIL上的GPR56表达,而健康供者原代人T细胞并无此变化。

此外,异位表达GPR56显著降低GPR56阳性T细胞的迁移能力。综上,GPR56可能是EOC中表达于(预)耗竭CD8 TIL上的免疫检查点,并可能调节其迁移行为。

展开英文摘要原文

High levels of tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment (TME) are associated with a survival benefit in various cancer types and the targeted (re)activation of TILs is an attractive therapeutic anti-cancer approach that yields curative responses.

However, current T cell targeting strategies directed at known immune checkpoints have not increased objective response rates for all cancer types, including for epithelial ovarian cancer (EOC). For this reason, the identification of new immune checkpoints that regulate T cell immunity remains of great interest. One yet largely uninvestigated checkpoint of potential interest is the G protein-coupled receptor 56 (GPR56), which belongs to the adhesion GPCR family.

GPR56 was originally reported to function in cerebral cortical development and in anti-depressant response, but also in cancer. Recently, GPR56 was identified as an inhibitory receptor expressed on human NK cells that by cis-interaction with the tetraspanin CD81 attenuated the cytotoxic activity of NK cells.

This NK cell checkpoint could be blocked by an GPR56 antibody, leading to increased cytotoxicity. Interestingly, GPR56 expression has also been reported on cytokine producing memory CD8 T lymphocytes and may thus represent a T cell checkpoint as well.

Here, GPR56 mRNA expression was characterized in the context of TILs, with GPR56 expression being detected predominantly in tumor infiltrating CD8 T cells with a cytotoxic and (pre-)exhausted phenotype. In accordance with this mRNA profile, TILs from ovarian cancer patients expressed GPR56 primarily within the effector memory and central memory T cell subsets. On T cells from healthy donors the expression was limited to effector memory and terminally differentiated T cells.

Notably, GPR56 expression further increased on TILs upon T cell receptor (TCR)-mediated stimulation in co-cultures with cancer cells, whereas GPR56 expression on healthy primary human T cells did not.

Further, the ectopic expression of GPR56 significantly reduced the migration of GPR56-positive T cells. Taken together, GPR56 is a potential immune-checkpoint in EOC found on (pre-)exhausted CD8 TILs that may regulate migratory behavior.

论文信息

作者
Bilemjian V、Vlaming MR、Álvarez Freile J、Huls G、De Bruyn M、Bremer E
单位
Department of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.Netherlands
期刊
Cancers2022 Jun 28
原文标识
PubMed 35804934 · DOI 10.3390/cancers14133164